The finding could lead to new TRIM5a-based treatments that would knock out HIV in humans, said senior researcher Edward M. Campbell, PhD, of Loyola University Health System.
Campbell and colleagues report their findings in an article featured on the cover of the Sept. 15, 2010 issue of the journal Virology, now available online.
In 2004, other researchers reported that TRIM5a protects rhesus monkeys from HIV. The TRIM5a protein first latches on to a HIV virus, then other TRIM5a proteins gang up and destroy the virus.
Humans also have TRIM5a, but while the human version of TRIM5a protects against some viruses, it does not protect against HIV.
Researchers hope to turn TRIM5a into an effective therapeutic agent. But first they need to identify the components in TRIM5a that enable the protein to destroy viruses. “Scientists have been trying to develop antiviral therapies for only about 75 years,” Campbell said. “Evolution has been playing this game for millions of years, and it has identified a point of intervention that we still know very little about.”
TRIM5a consists of nearly 500 amino acid subunits. Loyola researchers have identified six 6 individual amino acids, located in a previously little-studied region of the TRIM5a protein, that are critical in the ability of the protein to inhibit viral infection. When these amino acids were altered in human cells, TRIM5a lost its ability to block HIV-1 infection. (The research was done on cell cultures; no rhesus monkeys were used in the study.)
By continuing to narrow their search, researchers hope to identify an amino acid, or combination of amino acids, that enable TRIM5a to destroy HIV. Once these critical amino acids are identified, it might be possible to genetically engineer TRIM5a to make it more effective in humans. Moreover, a better understanding of the underlying mechanism of action might enable the development of drugs that mimic TRIM5a action, Campbell said.
In their research, scientists used Loyola’s wide-field “deconvolution” microscope to observe how the amino acids they identified altered the behavior of TRIM5a. They attached fluorescent proteins to TRIM5a to, in effect, make it glow. In current studies, researchers are fluorescently labeling individual HIV viruses and measuring the microscopic interactions between HIV and TRIM5a.
“The motto of our lab is one of Yogi Berra’s sayings — ‘You can see a lot just by looking,'” Campbell said.
Campbell is an assistant professor in the Department of Microbiology and Immunology at Loyola University Chicago Stritch School of Medicine. His co-authors are Jaya Sastri, a Stritch graduate student and first author; Christopher O’Connor, a former post-doctorate researcher at Stritch; Cindy Danielson and Michael McRaven of Northwestrn University Feinberg School of Medicine and Patricio Perez and Felipe Diaz-Griffero of Albert Einstein College of Medicine.
The study was supported by a grant from the National Institutes of Health.
Based in the western suburbs of Chicago, Loyola University Health System is a quaternary care system with a 61-acre main medical center campus, the 36-acre Gottlieb Memorial Hospital campus and 28 primary and specialty care facilities in Cook, Will and DuPage counties. The medical center campus is conveniently located in Maywood, 13 miles west of the Chicago Loop and 8 miles east of Oak Brook, Ill. The heart of the medical center campus, Loyola University Hospital, is a 561-licensed-bed facility. It houses a Level 1 Trauma Center, a Burn Center and the Ronald McDonald® Children’s Hospital of Loyola University Medical Center. Also on campus are the Cardinal Bernardin Cancer Center, Loyola Outpatient Center, Center for Heart & Vascular Medicine and Loyola Oral Health Center as well as the LUC Stritch School of Medicine, the LUC Marcella Niehoff School of Nursing and the Loyola Center for Fitness. Loyola’s Gottlieb Memorial Hospital campus in Melrose Park includes the 264-bed community hospital, the Gottlieb Center for Fitness and the Marjorie G. Weinberg Cancer Care Center.